This document summarizes recent developments in several countries' policies around capping the prices of generic drugs relative to the prices of their brand-name equivalents. It finds that many European countries as well as Canada, Japan, and others have lowered their price caps for generics in recent years, with caps now ranging from 25-70% of the originator price. While price caps remain a popular cost containment tool, internal reference pricing is also typically used. The tighter generic price caps aim to reduce pharmaceutical spending while raising out-of-pocket costs for patients.